XXII: Rasio kapitalisasi marang pendapatan 22nd Century Group

Stable cash flow from contract manufacturing supports 22nd Century Group (XXII), creating a foundation for growth. Breeding patents and FDA plans to reduce nicotine further enhance this potential. The P/S time series on the GURU.Markets chart reflects valuation dynamics, where the 0.00 level captures recent values. Its status as a biotech leader in national health confirms the brand's uniqueness.

Investors must determine whether the market value of 22nd Century Group (XXII) is overvalued against the backdrop of current operational risks. By analyzing the price-to-sales ratio, we compare market capitalization with sales volume, which is critical for a holding company undergoing a painful transition to contract manufacturing and asset divestment to stabilize its balance sheet.